The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.
 
Anna M. Varghese
Consulting or Advisory Role - Roche (I); Roche (I); Roche (I); Roche (I)
Research Funding - BioMed Valley Discoveries; BioMed Valley Discoveries; BioMed Valley Discoveries; BioMed Valley Discoveries; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Illumina (I); Illumina (I); Illumina (I); Illumina (I); Lilly; Lilly; Lilly; Lilly; Silenseed; Silenseed; Silenseed; Silenseed; Verastem; Verastem; Verastem; Verastem
Travel, Accommodations, Expenses - Roche (I); Roche (I); Roche (I); Roche (I)
 
Isha Singh
No Relationships to Disclose
 
Ritu Raj Singh
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Winston Wong
No Relationships to Disclose
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Adverum (I); Adverum (I); Adverum (I); Alimera Sciences (I); Alimera Sciences (I); Alimera Sciences (I); Alimera Sciences (I); Allergan (I); Allergan (I); Allergan (I); Allergan (I); Biomarin (I); Biomarin (I); Biomarin (I); Biomarin (I); Fortress Biotech (I); Fortress Biotech (I); Fortress Biotech (I); Fortress Biotech (I); Genentech/Roche (I); Genentech/Roche (I); Genentech/Roche (I); Genentech/Roche (I); Novartis (I); Novartis (I); Novartis (I); Novartis (I); Optos (I); Optos (I); Optos (I); Optos (I); Regeneron (I); Regeneron (I); Regeneron (I); Regeneron (I); Regenxbio (I); Regenxbio (I); Regenxbio (I); Regenxbio (I); Spark Therapeutics (I); Spark Therapeutics (I); Spark Therapeutics (I); Spark Therapeutics (I)
 
Erin E. Salo-Mullen
No Relationships to Disclose
 
Christine A Iacobuzio-Donahue
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
 
David Paul Kelsen
Consulting or Advisory Role - Kitov Pharmaceuticals; Kitov Pharmaceuticals; Kitov Pharmaceuticals; Kitov Pharmaceuticals; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Steba Biotech; Steba Biotech; Steba Biotech; Steba Biotech
Patents, Royalties, Other Intellectual Property - Use of Iron Containing Particles for Imaging by MRI; Use of Iron Containing Particles for Imaging by MRI; Use of Iron Containing Particles for Imaging by MRI; Use of Iron Containing Particles for Imaging by MRI
 
Wungki Park
Honoraria - Ipsen; Ipsen; Ipsen; Ipsen
Research Funding - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Gossamer Bio; Gossamer Bio; Gossamer Bio; Gossamer Bio; Merck; Merck; Merck; Merck
 
Kenneth H. Yu
Consulting or Advisory Role - celgene; celgene; celgene; celgene; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merrimack; Merrimack; Merrimack; Merrimack
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst)